![Joana Vidal Barrull](https://www.mskcc.org/sites/default/files/styles/large/public/node/179449/3x2/barrull_190506_06_1200x800.jpg)
My research interests are characterizing cell-free DNA. Using in vitro methods, I am working to define the underlying biological mechanisms of these molecules to improve its use as a biomarker for residual disease.
Publications
Montagut C; Argilés, G; Ciardiello F; Poulsen T; Dienstmann R; Kragh M; Kopetz S; Lindsted T; Ding C; Vidal J; Clausell-Tormos, J; Siravegna G; Sánchez-Martín F; Koefoed K; Pedersen MW; Grandal M; Dvorkin, M; Wyrwicz L; Rovira A; Cubillo A; Salazar R; Desseigne F; Nadal C; Albanell J; Zagonel V; Siena S; Fumi G; Rospo G; Nadler P; Horak I.D; Bardelli A; Tabernero J. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018 Apr 12;4(4):e175245.
Van Emburgh B, Arena S, Siravegna G, Lazzari L, Crisafulli, Corti, Mussolin B, Baldi, Buscarino, Bartolini, Valtorta, Vidal J, Bellosillo B, Germano, Pietrantonio, Ponzetti, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio B, Montagut C, Bardelli A (CM and AB ara co-corresponding). Emergence of RAS or EGFR extracellular domain mutations and duration of response to EGFR blockade in colorectal cancer. Nat Comm. 2016; 7:13665.